Group | n | CR | PR | MR | SD | PD | Response rate | p* | |
---|---|---|---|---|---|---|---|---|---|
NSCLC | Trial | 17 | 1 | 7 | 3 | 4 | 2 | 47.06% (8/17) | 0.208 |
Control | 6 | 0 | 1 | 1 | 3 | 1 | 16.67% (1/6) | ||
Gastric cancer | Trial | 32 | 0 | 4 | 6 | 13 | 9 | 12.50% (4/32) | 0.283 |
Control | 18 | 0 | 0 | 2 | 9 | 7 | 0.00 (0/18) | ||
Colorectal cancer | Trial | 20 | 0 | 1 | 2 | 10 | 7 | 5.00% (1/20) | 1.000 |
Control | 12 | 0 | 0 | 1 | 7 | 4 | 0.00 (0/12) |